SCHEMBL5378950

SCHEMBL5378950

C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H](C(C)C=O)CC[C@@H]23)C[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H]1O[Si](C)(C)C(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ VDR P11473 15/20 0.47
▸ NR1I2 O75469 2/20 0.46
▸ PGR P06401 2/20 0.46
▸ ADORA3 P0DMS8 2/20 0.46
▸ SLC6A2 P23975 2/20 0.46
▸ SLC6A4 P31645 2/20 0.46
▸ ADRA1A P35348 2/20 0.46
▸ PTGS2 P35354 2/20 0.46
▸ HTR1A P08908 1/20 0.46
▸ MAPT P10636 2/20 0.46
▸ ABCB11 O95342 1/20 0.46
▸ GC P02774 1/20 0.46
▸ RXRA P19793 1/20 0.46
▸ CHRM3 P20309 1/20 0.46
▸ CNR1 P21554 1/20 0.46
▸ HTR2C P28335 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ AGTR1 P30556 1/20 0.46
▸ OPRD1 P41143 1/20 0.46
▸ OPRK1 P41145 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5390580 1.00 VDR (0.47) VDRNR1I2PGRADORA3SLC6A2
SCHEMBL8773164 1.00 VDR (0.47) VDRNR1I2PGRADORA3SLC6A2
SCHEMBL5379816 1.00 VDR (0.47) VDRNR1I2PGRADORA3SLC6A2
SCHEMBL7154542 1.00 VDR (0.47) VDRNR1I2PGRADORA3SLC6A2
SCHEMBL5680998 1.00 VDR (0.47) VDRNR1I2PGRADORA3SLC6A2
SCHEMBL5385262 1.00 VDR (0.47) VDRNR1I2PGRADORA3SLC6A2
SCHEMBL25310518 1.00 VDR (0.47) VDRNR1I2PGRADORA3SLC6A2
SCHEMBL8527611 1.00 VDR (0.47) VDRNR1I2PGRADORA3SLC6A2
SCHEMBL7151478 1.00 VDR (0.47) VDRNR1I2PGRADORA3SLC6A2
SCHEMBL5382736 0.92 VDR (0.52) VDRNR1I2PGRADORA3SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195488-A1 MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE TEIJIN PHARMA LIMITED (JP) 2025-06-19 — — US disclosed
EP-4491185-A1 MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE Teijin Pharma Limited (JP) 2025-01-15 — — EP disclosed
US-20230348376-A1 VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN TEIJIN PHARMA LIMITED (JP) 2023-11-02 — — US disclosed
WO-2023171736-A1 MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE 帝人ファーマ株式会社 2023-09-14 — — WO disclosed
EP-4215519-A1 VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN Teijin Pharma Limited (JP) 2023-07-26 — — EP disclosed
US-7211680-B2 Vitamin D derivatives with carbo-or heterocyclic substituents at C-25, a process for their production, intermediate products and their use for producing medicaments SCHERING AKTIENGESELLSCHAFT (DE) 2007-05-01 — — US disclosed
US-7071344-B1 Vitamin D derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilization thereof for producing medicaments SCHERING AG (DE) 2006-07-04 — — US disclosed
US-20050227951-A1 Verification of translation STEINMEYER ANDREAS 2005-10-13 — — US disclosed
US-20050080058-A1 New vitamin D derivatives with carbo-or heterocyclic substituents at C-25, a process for their production, intermediate products and their use for producing medicaments SCHERING AKTIENGESELLSCHAFT PATENTS (DE) 2005-04-14 — — US disclosed
US-6642218-B2 (5Z,7E,22E)-(1S,3R,24R)-25-(5-Propyloxazol-2-yl)-26,27-cyclo -9,10-secocholesta-5,7,10(19), 22-tetraene-1,3,24-triol for treatment of diseases characterized by hyperproliferation and deficient cell differentiation SCHERING AKTIENGESELLSCHAFT (DE) 2003-11-04 — — US disclosed
EP-0900198-B1 NEW VITAMIN D DERIVATIVES WITH CARBO- OR HETEROCYCLIC SUBSTITUENTS AT C-25, A PROCESS FOR THEIR PRODUCTION, INTERMEDIATE PRODUCTS AND THEIR USE FOR PRODUCING MEDICAMENTS SCHERING AG (DE) 2003-03-12 — — EP disclosed
US-6531459-B1 Therapy of or prophylaxis against osteoporosis; generating new bone material; treating disease characterized by hyperproliferation and deficient cell differentiation SCHERING AKTIENGESELLSCHAFT (DE) 2003-03-11 — — US disclosed
US-20030018194-A1 New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents STEINMEYER ANDREAS (DE) 2003-01-23 — — US disclosed
US-20020049344-A1 NEW VITAMIN D DERIVATIVES WITH CARBO-OR HETEROCYCLIC SUBSTITUENTS AT C-25, A PROCESS FOR THEIR PRODUCTION, INTERMEDIATE PRODUCTS AND THEIR USE FOR PRODUCING MEDICAMENTS SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-25 — — US disclosed
US-6376480-B1 TREATMENT OF IMMUNE SYSTEM DISORDERS, OSTEOPOROSIS, ALOPECIA SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-23 — — US disclosed
US-6372731-B1 TREATMENT OF CELL PROLIFERATION AND BONE DISORDERS SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-16 — — US disclosed
EP-1025082-A1 NOVEL VITAMIN D DERIVATIVES WITH CYCLOPROPYL RINGS IN THE LATERAL CHAINS, A METHOD AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION THEREOF AND THE UTILIZATION THEREOF FOR PRODUCING MEDICAMENTS SCHERING AKTIENGESELLSCHAFT (DE) 2000-08-09 — — EP disclosed
EP-0832063-B1 VITAMIN D DERIVATIVES WITH C-25 SUBSTITUENTS, PROCESS FOR THEIR PREPARATION, INTERMEDIATE PRODUCTS AND THEIR USE IN PREPARING MEDICAMENTS SCHERING AG (DE) 2000-02-23 — — EP disclosed
EP-0927721-A1 Novel vitamine D derivatives having phosphorus atoms in the side chains, intermediates for their preparation and their use for the preparation of drugs SCHERING AKTIENGESELLSCHAFT (DE) 1999-07-07 — — EP disclosed
WO-1999016745-A1 NOVEL VITAMIN D DERIVATIVES WITH CYCLOPROPYL RINGS IN THE LATERAL CHAINS, A METHOD AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION THEREOF AND THE UTILIZATION THEREOF FOR PRODUCING MEDICAMENTS SCHERING AKTIENGESELLSCHAFT (DE) 1999-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195488-A1 MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE VDR, CYP24A1, AQP4 VDR 1/4885NR1I2 1493/4885PGR 4399/4885
US-20020049344-A1 NEW VITAMIN D DERIVATIVES WITH CARBO-OR HETEROCYCLIC SUBSTITUENTS AT C-25, A PROCESS FOR THEIR PRODUCTION, INTERMEDIATE PRODUCTS AND THEIR USE FOR PRODUCING MEDICAMENTS CYP2R1, VDR, CYP24A1 VDR 2/4885NR1I2 392/4885PGR 890/4885
US-20050227951-A1 Verification of translation CYP2R1, CYP24A1, VDR VDR 3/4885NR1I2 1968/4885PGR 1344/4885
US-20230348376-A1 VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN VDR, CYP2R1, CYP24A1 VDR 1/4885NR1I2 1035/4885PGR 1939/4885
US-20030018194-A1 New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents CYP2R1, CYP24A1, VDR VDR 3/4885NR1I2 414/4885PGR 936/4885
US-20050080058-A1 New vitamin D derivatives with carbo-or heterocyclic substituents at C-25, a process for their production, intermediate products and their use for producing medicaments VDR, CYP24A1, CYP2R1 VDR 1/4885NR1I2 545/4885PGR 377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback